RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo
Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients
2006-01-01 E., Vasile; E., Giovannetti; C., Tibaldi; V., Mey; S., Nannizzi; L., Landi; I., Stasi; Danesi, Romano; M., DEL TACCA; Falcone, Alfredo
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients
2009-01-01 A., Ruzzo; Cremolini, Chiara; F., Loupakis; L., Fornaro; D., Santini; B., Vincenzi; E., Canestrari; M., Magnani; Falcone, Alfredo; F., Graziano
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC
2014-01-01 DEL RE, Marzia; Landi, L; Tiseo, M; Camerini, A; Petrini, Iacopo; Inno, A; Citi, V; Salvini, J; Minuti, Gabriele; Vasile, E; Falcone, Alfredo; Gori, S; Amoroso, D; Ardizzoni, A; Cappuzzo, F; Danesi, Romano
Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer (NSCLC/CRC).
2011-01-01 Giannarelli, D; Milella, M; Loupakis, F; Cuppone, F; Vaccaro, V; Sperduti, I; Carlini, P; Falcone, Alfredo; Cognetti, F; Bria, E.
Balancing pros and cons of the addition of Bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials exploring absolute benefits
2009-01-01 F., Cuppone; V., Vaccaro; F., Loupakis; M., Milella; P., Carlini; C., Nisticò; Falcone, Alfredo; D., Giannarelli; F., Cognetti; E., Bria
Bevacizumab (B) combined to chemotherapy for first-line treatment of elderly patients with advanced colorectal cancer (CRC): results from a large community-based Italian observational study.
2012-01-01 Ferrari, L; Schirripa, M; Calvetti, L; Rosati, G; Gianpieri, R; Avallone, A; Cordio, S; Berretta, M; ROJAS LLIMPE, F. L.; Loupakis, F; Scartozzi, M; Lonardi, S; Pinto, C; Falcone, Alfredo; Cascinu, S; Iaffaioli, V. R.; Bordonaro, R; Tirelli, U; Zagonel, V; Fasola, G; Aprile, G.
Bevacizumab (BV) in combination with folfoxiri (Irinotecan, Oxaliplatin and Infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO GROUP
2009-01-01 Masi, G.; Vasile, E.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Baldi, G.; Stasi, I.; Cupini, S.; Ciarlo, A.; DEL MONTE, F.; Trenta, P.; Mezi, S.; Rondini, M.; Andreuccetti, M.; Falcone, Alfredo
Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updates results of a phase II G.O.N.O. trial
2009-01-01 Masi, G.; Salvatore, L.; Fornaro, L.; Vasile, E.; Baldi, G. G.; Stasi, I.; Ciarlo, A.; Tuzi, A.; Andreuccetti, M.; Falcone, Alfredo
Bevacizumab (BV) in combination with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updates results of a phase II G.O.N.O. trial
2009-01-01 Vasile, E.; Masi, G.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Cupini, S.; DI MARSICO, R.; Antonuzzo, A.; Baldi, G. G.; Stasi, I.; Pfanner, E.; Ciarlo, A.; DEL MONTE, F.; Conte, D.; Iacovelli, R.; Sonaglio, C.; Granetto, C.; Donati, S.; Andreuccetti, M.; Falcone, Alfredo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
| Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients | 1-gen-2006 | E., Vasile; E., Giovannetti; C., Tibaldi; V., Mey; S., Nannizzi; L., Landi; I., Stasi; Danesi, Romano; M., DEL TACCA; Falcone, Alfredo | |
| Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients | 1-gen-2009 | A., Ruzzo; Cremolini, Chiara; F., Loupakis; L., Fornaro; D., Santini; B., Vincenzi; E., Canestrari; M., Magnani; Falcone, Alfredo; F., Graziano | |
| Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC | 1-gen-2014 | DEL RE, Marzia; Landi, L; Tiseo, M; Camerini, A; Petrini, Iacopo; Inno, A; Citi, V; Salvini, J; Minuti, Gabriele; Vasile, E; Falcone, Alfredo; Gori, S; Amoroso, D; Ardizzoni, A; Cappuzzo, F; Danesi, Romano | |
| Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer (NSCLC/CRC). | 1-gen-2011 | Giannarelli, D; Milella, M; Loupakis, F; Cuppone, F; Vaccaro, V; Sperduti, I; Carlini, P; Falcone, Alfredo; Cognetti, F; Bria, E. | |
| Balancing pros and cons of the addition of Bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials exploring absolute benefits | 1-gen-2009 | F., Cuppone; V., Vaccaro; F., Loupakis; M., Milella; P., Carlini; C., Nisticò; Falcone, Alfredo; D., Giannarelli; F., Cognetti; E., Bria | |
| Bevacizumab (B) combined to chemotherapy for first-line treatment of elderly patients with advanced colorectal cancer (CRC): results from a large community-based Italian observational study. | 1-gen-2012 | Ferrari, L; Schirripa, M; Calvetti, L; Rosati, G; Gianpieri, R; Avallone, A; Cordio, S; Berretta, M; ROJAS LLIMPE, F. L.; Loupakis, F; Scartozzi, M; Lonardi, S; Pinto, C; Falcone, Alfredo; Cascinu, S; Iaffaioli, V. R.; Bordonaro, R; Tirelli, U; Zagonel, V; Fasola, G; Aprile, G. | |
| Bevacizumab (BV) in combination with folfoxiri (Irinotecan, Oxaliplatin and Infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO GROUP | 1-gen-2009 | Masi, G.; Vasile, E.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Baldi, G.; Stasi, I.; Cupini, S.; Ciarlo, A.; DEL MONTE, F.; Trenta, P.; Mezi, S.; Rondini, M.; Andreuccetti, M.; Falcone, Alfredo | |
| Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updates results of a phase II G.O.N.O. trial | 1-gen-2009 | Masi, G.; Salvatore, L.; Fornaro, L.; Vasile, E.; Baldi, G. G.; Stasi, I.; Ciarlo, A.; Tuzi, A.; Andreuccetti, M.; Falcone, Alfredo | |
| Bevacizumab (BV) in combination with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updates results of a phase II G.O.N.O. trial | 1-gen-2009 | Vasile, E.; Masi, G.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Cupini, S.; DI MARSICO, R.; Antonuzzo, A.; Baldi, G. G.; Stasi, I.; Pfanner, E.; Ciarlo, A.; DEL MONTE, F.; Conte, D.; Iacovelli, R.; Sonaglio, C.; Granetto, C.; Donati, S.; Andreuccetti, M.; Falcone, Alfredo |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 4 Contributo in Atti di Convegno ... 322
- 4 Contributo in Atti di Convegno ... 275
- 4 Contributo in Atti di Convegno ... 46
- 4 Contributo in Atti di Convegno ... 1
Data di pubblicazione
- 2010 - 2019 154
- 2000 - 2009 160
- 1991 - 1999 8
Editore
- Oxford University Press 15
- Monduzzi Editore 2
- American Society of Clinical Onco... 1
- Centro Scientifico Editore 1
- CEPI Editore 1
- European Association for Endoscop... 1
- Excerpta Medica Italia 1
- Il Coccio 1
- Sintesi InfoMedica 1
- Springer-Verlag 1
Rivista
- JOURNAL OF CLINICAL ONCOLOGY 38
- TUMORI 35
- ANNALS OF ONCOLOGY 32
- EUROPEAN JOURNAL OF CANCER 2
- TUMOR BIOLOGY 2
- EUROPEAN JOURNAL OF CANCER. SUPPL... 1
- TUMORI 1
Lingua
- eng 298
- ita 10
Accesso al fulltext
- no fulltext 308
- open 14